Mark Leuchtenberger
President and Chief Executive Officer

Mark Leuchtenberger has been President & Chief Executive Officer of Targanta Therapeutics Corporation since September 2006 and led the company�s successful IPO in 2007. He joined Targanta from Therion Biologics Corporation, a privately held cancer vaccine company, where he served as President and Chief Executive Officer from 2002 to 2006. Under his leadership, Therion filed its first IND, progressed through Phase 3 trials, completed the buildup of its commercial manufacturing capabilities, and raised over $120 million in three rounds of private financings.

Prior to joining Therion, Mr. Leuchtenberger was a senior officer at Biogen, where he served as Vice President, International from 1999-2002. In this capacity, he led all commercial operations outside of North America. He joined Biogen in 1990 and was responsible for managing the late-stage development, registration, marketing, and North American launch of Avonex®. He subsequently served as Vice President of Sales, Marketing and Business Development, where he oversaw North American commercial operations as well as Biogen's global market, licensing and strategic partnership activities. Prior to Biogen, Mr. Leuchtenberger worked as a Senior Consultant at Bain and Company specializing in healthcare products and services.

Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University. He is currently the Chairman of the Massachusetts Biotechnology Council Board of Directors and also serves on Boards for EPIX Pharmaceuticals, Beth Israel Deaconess Medical Center, and Wake Forest University.